

2019 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

<https://marketpublishers.com/r/25336FE99C6EN.html>

Date: February 2019

Pages: 37

Price: US\$ 2,199.00 (Single User License)

ID: 25336FE99C6EN

Abstracts

The ongoing clinical trial research report- “2019 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials Study” analyzes the current scenario of all active Familial Chylomicronemia (Type I Hyperlipoproteinemia) trials across the world. The report presents top level analysis of global Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Familial Chylomicronemia (Type I Hyperlipoproteinemia) trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials by-

Region (Asia Pacific, Europe, Middle East Africa and Americas)

Countries

Trial Phase

Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)

Type of the trial (Interventional, Observational)

Sponsor Type (Companies, Universities, Government Bodies etc)

Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Familial Chylomicronemia (Type I Hyperlipoproteinemia) on the basis of intervention type ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) trials.

The research work is prepared through extensive and continuous research on Familial Chylomicronemia (Type I Hyperlipoproteinemia) trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:

All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.

Drug candidates currently being researched for administering Familial Chylomicronemia (Type I Hyperlipoproteinemia) patients are identified

The report includes panorama of ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials across the globe

Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided

Companies and universities focusing on Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)

Average Enrollment number, insights into enrollment trends, company wise enrollment are included

Both interventional and observational studies are analyzed

News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials Overview, 2019

2.2 Premium Insights into Ongoing Clinical Trials

2.2.1 Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Region

2.2.2 Average Enrollment of Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials

2.2.3 Companies participating in Ongoing Trials

2.2.4 Drugs under Study for Familial Chylomicronemia (Type I Hyperlipoproteinemia) Treatment, 2019

3. REGION WISE FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) CLINICAL TRIALS

3.1 Asia Pacific Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country

3.2 Europe Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country

3.3 North America Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country

3.4 Middle East and Africa Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country

3.5 South and Central America Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials by Country

4. FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials

4.2 Phase wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Clinical Trials

4.3 Trial Status wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Clinical Trials

4.4 Trial Type wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Clinical Trials

5. FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Trials by Year

5.2 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Trials by Phase

5.3 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Trials by Status

5.4 Average Enrollment in Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING FAMILIAL CHYLOMICRONEMIA (TYPE I HYPERLIPOPROTEINEMIA) CLINICAL TRIALS

6.1 Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials by Sponsor
Type

6.2 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by
Sponsor Type

6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase

7.2 Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase

7.3 Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase

7.4 Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Trials- Phase

8. APPENDIX

- 8.1 Report Guidance
- 8.2 Research Methodology
- 8.3 Abbreviations
- 8.4 Definitions
- 8.5 Sources
- 8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials by Region, 2019

Figure 2: Country wise Clinical Trials, 2019

Figure 3: Country wise Average Enrolment, 2019

Figure 4: Asia Pacific – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Figure 5: Europe – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Figure 6: Middle East Africa – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Figure 7: North America – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Figure 8: South and Central America – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Figure 9: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials by Phase

Figure 10: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials by Trial Status

Figure 11: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials by Type

Figure 12: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials by Sponsor Type

Figure 13: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials by Leading Sponsors

Figure 14: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Phase

Figure 15: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Trial Status

Figure 16: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Type

Figure 17: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Average Enrolment by Type of Sponsors

Figure 18: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Enrolment by Leading Sponsors

Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Ongoing Clinical Trials Snapshot- 2019

Table 2: Ongoing Trials by Region, 2019

Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019

Table 4: Asia Pacific – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Table 5: Europe – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Table 6: Middle East Africa – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Table 7: North America – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Table 8: South and Central America – Country wise Ongoing Familial Chylomicronemia (Type I Hyperlipoproteinemia) Clinical Trials and Enrolment

Table 9: Clinical Trials by Phase

Table 10: Clinical Trials by Trial Status

Table 11: Clinical Trials by Type

Table 12: Clinical Trials by Sponsor Type

Table 13: Clinical Trials by Leading Sponsors

Table 14: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Phase

Table 15: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Trial Status

Table 16: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Average Enrollment by Type

Table 17: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Average Enrolment by Type of Sponsors

Table 18: Familial Chylomicronemia (Type I Hyperlipoproteinemia)- Enrolment by Leading Sponsors

